Search

A recent study conducted by researchers at Northwestern University focused on primary graft dysfunction (PGD) in patients undergoing lung transplantation for chronic and acute respiratory failure. The study found contrasting risk factors for severe PGD in patients with acute respiratory distress syndrome (ARDS) compared to those with chronic respiratory failure. The research highlighted the need for tailored approaches in managing these distinct patient populations and suggested further research to refine strategies aimed at reducing PGD incidence and enhancing transplant outcomes. [Extracted from the article]

A study conducted at Ludwig-Maximilians-University Munich explored the use of lung ultrasound as a diagnostic tool for primary graft dysfunction following lung transplantation. The research found a significant correlation between B-line scores obtained through lung ultrasound and the diagnosis of primary graft dysfunction, outperforming chest radiographs in accuracy. The study concluded that B-lines showed promise in detecting primary graft dysfunction and could potentially improve diagnostic capabilities in transplant medicine. [Extracted from the article]

Researchers at the University of Virginia conducted a study on the use of a TRPV4 inhibitor to reduce lung ischemia-reperfusion injury in a porcine lung transplant model. The study involved administering the inhibitor to recipients after transplant, resulting in improved lung function, reduced injury, and inflammation markers. The research suggests that selective TRPV4 inhibition could be a promising therapeutic approach to prevent primary graft dysfunction after transplant. [Extracted from the article]

This article discusses a study on predicting primary graft dysfunction (PGD) in lung transplantation using machine learning-guided biomarker discovery. The researchers collected biospecimens from multiple sites in patients undergoing lung transplantation and performed a multiplex panel analysis. They used logistic regression and random forest machine learning models to determine which analytes could discriminate between different grades of PGD. The study found that bronchoalveolar lavage fluid collected 2 hours post-transplant was the most predictive of severe PGD. The researchers also identified novel cytokines that could be used as a point-of-care cytokine panel to identify those at risk for developing severe PGD. [Extracted from the article]

A recent report from Northwestern University Feinberg School of Medicine in Chicago, Illinois, explores the impact of pretransplant blood transfusions on primary graft dysfunction (PGD) after lung transplantation. The study, which involved 206 lung transplantations, found that pretransplantation transfusions were strongly associated with a higher incidence of PGD grade 3 (PGD 3). However, there was no significant difference in one-year survival between the transfused and non-transfused groups. The research suggests that pretransplantation blood transfusions may carry potential risks for lung transplant recipients. [Extracted from the article]

A report from the University Medical Center Utrecht in the Netherlands discusses research findings on primary graft dysfunction (PGD) in lung transplantation. The study highlights the poor long-term outcomes of lung transplantation, with a high percentage of patients developing chronic lung allograft dysfunction (CLAD). The researchers propose an integrated approach to assess, modify, and match risk factors in order to reduce the risk of inflammatory-type PGD and improve survival rates. The use of ex vivo lung perfusion (EVLP) is also explored as a potential platform for targeted therapeutic interventions on lung allografts. [Extracted from the article]

Researchers from Ohio State University Wexner Medical Center have published findings on primary graft dysfunction (PGD) following lung transplantation. The study analyzed data from the United Network for Organ Sharing database and found that 21.4% of patients experienced PGD3, which was associated with worse perioperative morbidity, mortality, and long-term survival. The use of ex vivo lung perfusion (EVLP) prior to transplantation was found to decrease the likelihood of PGD3 development. The researchers concluded that further optimization of EVLP technology is necessary to expand the donor pool. [Extracted from the article]

A recent study conducted by researchers at the University of Pennsylvania examined the relationship between body mass index (BMI) and primary graft dysfunction (PGD) after lung transplantation. The study found that higher BMI increased the risk of developing PGD, but it did not appear to be associated with survival after PGD. The researchers suggest that future work should focus on preventing PGD in patients with obesity rather than managing it. This information is important for individuals considering lung transplantation and healthcare professionals involved in transplant medicine. [Extracted from the article]

A recent study conducted by researchers at the Catholic University of Louvain (UCLouvain) in Belgium explores the relationship between left ventricular diastolic pressure and primary graft dysfunction (PGD) after lung transplantation. PGD is a severe lung injury that occurs within 72 hours of transplantation and is the leading cause of early death after the procedure. The study aims to summarize the mechanisms, risk factors, and diagnostic criteria for PGD, with a specific focus on the interplay between left ventricular diastolic dysfunction and PGD development. The researchers also investigate the predictive value of various diagnostic parameters for diastolic dysfunction in predicting the occurrence and severity of PGD. [Extracted from the article]

A recent study aimed to identify biomarkers that could predict the risk of primary graft dysfunction (PGD) in lung transplantation. The researchers collected biospecimens from multiple sites in patients undergoing bilateral lung transplants and performed a multiplex panel analysis. They used machine learning models to determine which analytes could discriminate between different grades of PGD. The study found that bronchoalveolar lavage fluid collected 2 hours post-transplant was the most predictive of severe PGD. The researchers also identified novel cytokines that could be used as a point-of-care panel to identify those at risk for developing severe PGD. [Extracted from the article]

A recent study from the Mayo Clinic explores primary graft dysfunction (PGD) in heart transplantation. PGD is a life-threatening condition that occurs within 24 hours of transplantation and is characterized by dysfunction of the transplanted heart. The exact causes and mechanisms of PGD are not fully understood, but factors such as myocardial damage, proinflammatory mediators, and ischemia-reperfusion injury are believed to play a role. The study aims to review the existing literature on PGD and provide insights into its diagnosis, pathophysiology, risk factors, treatment, and perioperative management. [Extracted from the article]

A recent report from the University of Pennsylvania discusses the development and validation of a predictive algorithm for primary graft dysfunction (PGD) in lung transplant candidates. PGD is a major cause of morbidity and mortality after lung transplantation, and accurate prediction of PGD risk could improve donor selection and perioperative care planning. The researchers developed a predictive model using various clinical factors and created a user interface for real-time assessment of PGD risk. The algorithm offers decision-making support and can be used to enrich samples for PGD treatment trials. [Extracted from the article]

A study conducted by researchers at Northwestern University in Chicago, Illinois, explores the relationship between complement activation and primary graft dysfunction (PGD) in lung transplant patients. The study found that early complement deposition in the allografts was highly predictive of severe PGD at 72 hours post-transplant. Patients with positive C4d staining were more likely to develop PGD-3 and experienced worse long-term outcomes. The researchers suggest that further studies should be conducted to evaluate the role of complement inhibition in mitigating PGD and improving transplant outcomes. [Extracted from the article]

A recent report from Washington University discusses the development of machine learning models to predict primary graft dysfunction (PGD) after lung transplantation. PGD is a major cause of morbidity and mortality in the first 30 days after transplantation. The study used donor and recipient variables known at the time of donor offer acceptance to develop predictive models. The final model showed promising results with an area under the receiver operating characteristics curve of 0.65. This research has the potential to improve donor-recipient matching and donor utilization in the future. [Extracted from the article]

A study conducted by researchers at the University of Pennsylvania has found that donor smoking is associated with a modest increase in the risk of primary graft dysfunction (PGD) after lung transplantation. However, donor smoking does not appear to be linked to increased recipient mortality. The study suggests that the use of lungs from smokers may be safe and could potentially increase the availability of lung donors. The research was supported by the National Institutes of Health and has been published in the American Journal of Respiratory and Critical Care Medicine. [Extracted from the article]

A study conducted at Cedars Sinai Medical Center in Los Angeles, California, examined the association between pretransplant human leukocyte antigen (HLA) sensitization and the risk of primary graft dysfunction (PGD) after heart transplantation. The study found that sensitization for all HLA loci, particularly HLA-A, was associated with an increased severity of PGD. Factors such as recipient beta-blocker use, total ischemic time, donor age, prior cardiac surgery, and United Network for Organ Sharing status 1 or 2 were also associated with increased severity of PGD. The researchers suggest that these factors should be considered in pre-transplant risk stratification to minimize the risk of PGD. [Extracted from the article]

A recent study conducted at Ohio State University examined the long-term survival rates of patients who developed primary graft dysfunction (PGD) following lung transplantation. PGD is a known risk factor for early mortality after transplantation, but little is known about the outcomes for patients who survive the initial hospitalization. The study found that patients with severe PGD had increased length of stay, dialysis, and treated rejection post-transplant. However, after adjusting for other factors, PGD3 was not independently associated with decreased long-term survival. The researchers recommend that transplant providers focus on preventing complications in patients with severe PGD to improve long-term outcomes. [Extracted from the article]

A study conducted by researchers at Nebraska Medicine in Omaha, Nebraska, examined the effects of preoperative amiodarone on primary graft dysfunction (PGD) in heart transplant patients. The study found that cumulative preoperative amiodarone exposure increased the odds of severe PGD at 3 and 6 months post-transplant. Patients on amiodarone also had higher rates of postoperative bradycardia. The researchers concluded that the findings are clinically concerning and highlight the need for further investigation. The study was published in the Annals of Pharmacotherapy. [Extracted from the article]

A study conducted at Duke University Medical Center in Durham, North Carolina, explored the optimal allograft sizing strategy for lung transplantation in restrictive lung disease. The researchers developed a new sizing ratio that incorporated preoperative recipient computed tomographic lung volumes (CTVol) and found that undersizing based on this volumetric ratio was associated with decreased primary graft dysfunction. On the other hand, oversizing based on the volumetric ratio was linked to an increased risk of death. The study suggests that using computed tomography-acquired lung volumes for donor-recipient size matching in lung transplantation may be more predictive of outcomes compared to current methods. [Extracted from the article]

A recent study conducted at Mayo Clinic Arizona has examined the risk factors associated with primary graft dysfunction (PGD) following lung transplantation. PGD is a significant cause of morbidity and mortality in lung transplant recipients. The study reviews the current literature on PGD and discusses strategies to mitigate its occurrence. The researchers also highlight recent advancements in lung transplantation techniques and the impact of the COVID-19 pandemic. For more information, the full article can be accessed for free through Frontiers in Immunology. [Extracted from the article]

A recent report from Okayama University Hospital in Japan explores the relationship between plasma concentrations of histidine-rich glycoprotein and the risk of primary graft dysfunction after lung transplantation. The study found that patients with lower plasma histidine-rich glycoprotein concentrations at 72 hours post-transplantation were more likely to develop severe primary graft dysfunction. Additionally, patients with higher concentrations of histidine-rich glycoprotein had better overall survival and chronic lung allograft dysfunction-free survival. This research suggests that plasma histidine-rich glycoprotein concentrations may be associated with the risk of primary graft dysfunction. [Extracted from the article]

A new report from the Albert Einstein College of Medicine presents fresh data on primary graft dysfunction (PGD) after cardiac transplantation. The study focused on the use of extracorporeal membrane oxygenation (ECMO) for treating severe PGD. The researchers found that using a peripheral and ventless ECMO approach was effective, with high rates of graft recovery and survival. This research provides valuable insights into the treatment of PGD after heart transplant. [Extracted from the article]

A research report from Zhengzhou University in China discusses the involvement of a specific gene, H19, in primary graft dysfunction (PGD) following lung transplantation. The study used high-throughput sequencing analysis to identify differential long noncoding RNAs and messenger RNAs for coexpression analysis. The researchers found that H19 promotes PGD by increasing the expression of the transcription factor KLF5, which in turn leads to the activation of CCL28. Silencing H19 reduced inflammation and improved PGD. This study provides new insights into the mechanism of action of H19 in PGD. [Extracted from the article]

A recent study conducted by researchers from Northwestern University in Chicago, Illinois, has found that high postreperfusion systolic pulmonary artery pressure may be a clinical marker for primary graft dysfunction after lung transplant. The study, which included 158 consecutive lung transplants performed at a single academic center, found that patients with primary graft dysfunction had higher postreperfusion systolic pulmonary artery pressure compared to those without. The researchers concluded that using postreperfusion systolic pulmonary artery pressure as an indicator of primary graft dysfunction could allow for earlier intervention and potentially improve outcomes. This research has been peer-reviewed and published in The Annals of Thoracic Surgery. [Extracted from the article]

A recent study conducted by researchers at the University of Gothenburg explores the use of non-ischaemic heart preservation as an alternative to the current gold standard of ischaemic cold static storage (ICSS) in heart transplantation. The study, called the NIHP 2019 study, is an international, randomised, controlled, multicentre clinical trial involving 202 patients undergoing heart transplantation in 15 heart transplantation centres across eight European countries. The primary objective of the study is to evaluate the effect of non-ischaemic heart preservation on survival, allograft function, and rejection episodes within the first 30 days after transplantation. The study has been approved by multiple ethics committees and will be conducted in accordance with current regulations and international requirements. The results of the study will be published in due course. [Extracted from the article]

A report from Duke University discusses new research on primary graft dysfunction (PGD) after heart transplantation. The study aimed to determine if recipient administration of thyroid hormone (T3) is associated with reduced rates of PGD. The study included 609 adult heart transplant recipients divided into two groups: those who did not receive T3 and those who did. The results showed that T3 supplementation did not significantly reduce the incidence of PGD or mortality rates. However, patients in the T3 group were less likely to develop severe PGD. The study suggests that while T3 administration may not prevent PGD, it may lessen its severity. [Extracted from the article]

"An exemplary method can include collecting a sample from the subject, measuring in the sample, a level of a marker predictive of post-transplant survival, providing a transplant risk value that is quantified based on the level of the marker using an adaptive Monte Carlo cross-validation (MCCV) model, and predicting the likelihood of post-transplant survival based on the transplant risk value. A method for predicting post-transplant survival of a subject seeking an organ transplant comprising: collecting a sample from the subject; measuring in the sample, a level of a marker predictive of post-transplant survival; providing a transplant risk value that is quantified based on the level of the marker using an adaptive Monte Carlo cross-validation (MCCV) model; and predicting the likelihood of post-transplant survival based on the transplant risk value. Tools that can accurately classify post-transplant risk have been developed for other solid organ transplants, such as kidney and lung, but similar efforts to predict post-transplant survival in heart transplantation have had limited success. [Extracted from the article]

Keywords: Chicago; State:Illinois; United States; North and Central America; Acute Kidney Injury; Biomedicine; Cardiovascular Diseases and Conditions; Chronic Kidney Disease; Experimental Lung Transplants; Health and Medicine; Kidney Diseases and Conditions; Primary Graft Dysfunction; Reperfusion Injury; Surgery; Transplant Medicine; Vascular Diseases and Conditions EN Chicago State:Illinois United States North and Central America Acute Kidney Injury Biomedicine Cardiovascular Diseases and Conditions Chronic Kidney Disease Experimental Lung Transplants Health and Medicine Kidney Diseases and Conditions Primary Graft Dysfunction Reperfusion Injury Surgery Transplant Medicine Vascular Diseases and Conditions 123 123 1 08/07/23 20230807 NES 230807 2023 AUG 10 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Current study results on Cardiovascular Diseases and Conditions - Primary Graft Dysfunction have been published. For more information on this research see: Primary Graft Dysfunction Grade Correlates With Acute Kidney Injury Stage After Lung Transplantation. [Extracted from the article]

Biomedicine, Cardiovascular Diseases and Conditions, Experimental Lung Transplants, Health and Medicine, Primary Graft Dysfunction, Reperfusion Injury, Surgery, Transplant Medicine, Vascular Diseases and Conditions Keywords: Biomedicine; Cardiovascular Diseases and Conditions; Experimental Lung Transplants; Health and Medicine; Primary Graft Dysfunction; Reperfusion Injury; Surgery; Transplant Medicine; Vascular Diseases and Conditions EN Biomedicine Cardiovascular Diseases and Conditions Experimental Lung Transplants Health and Medicine Primary Graft Dysfunction Reperfusion Injury Surgery Transplant Medicine Vascular Diseases and Conditions 334 334 1 08/07/23 20230807 NES 230807 2023 AUG 10 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- A new study on primary graft dysfunction is now available. [Extracted from the article]

Keywords: Biomedicine; Cardiovascular Diseases and Conditions; Digestive System Diseases and Conditions; Drugs and Therapies; Experimental Lung Transplants; Gastroenterology; Genetics; Health and Medicine; Hepatitis; Hepatitis C Virus; Hepatology; Infectious Disease; Infectious Diseases and Conditions; Liver Diseases and Conditions; Primary Graft Dysfunction; Reperfusion Injury; Risk and Prevention; Surgery; Therapy; Transplant Medicine; Vascular Diseases and Conditions; Virology EN Biomedicine Cardiovascular Diseases and Conditions Digestive System Diseases and Conditions Drugs and Therapies Experimental Lung Transplants Gastroenterology Genetics Health and Medicine Hepatitis Hepatitis C Virus Hepatology Infectious Disease Infectious Diseases and Conditions Liver Diseases and Conditions Primary Graft Dysfunction Reperfusion Injury Risk and Prevention Surgery Therapy Transplant Medicine Vascular Diseases and Conditions Virology 142 142 1 07/10/23 20230714 NES 230714 2023 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- New research on primary graft dysfunction is the subject of a new report. Recipients of hepatitis C virus nucleic acid test positive donor lungs underwent preemptive direct-acting antiviral therapy with glecaprevir 300 mg/pibrentasvir 120 mg for 8 weeks from January 1, 2019, to December 31, 2020.". [Extracted from the article]

For more information on this research see: Donor Hyperoxia Is a Novel Risk Factor for Severe Cardiac Primary Graft Dysfunction. Keywords: Los Angeles; State:California; United States; North and Central America; Cardiology; Cardiovascular Diseases and Conditions; Health and Medicine; Hyperoxia; Primary Graft Dysfunction; Reperfusion Injury; Risk and Prevention; Vascular Diseases and Conditions EN Los Angeles State:California United States North and Central America Cardiology Cardiovascular Diseases and Conditions Health and Medicine Hyperoxia Primary Graft Dysfunction Reperfusion Injury Risk and Prevention Vascular Diseases and Conditions 81 81 1 06/19/23 20230622 NES 230622 2023 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Investigators publish new report on Cardiovascular Diseases and Conditions - Primary Graft Dysfunction. [Extracted from the article]

For more information on this research see: Primary Graft Dysfunction After Lung Transplantation. Keywords: Philadelphia; State:Pennsylvania; United States; North and Central America; Biomedicine; Cardiovascular Diseases and Conditions; Experimental Lung Transplants; Health and Medicine; Inflammation; Primary Graft Dysfunction; Reperfusion Injury; Risk and Prevention; Surgery; Transplant Medicine; Vascular Diseases and Conditions EN Philadelphia State:Pennsylvania United States North and Central America Biomedicine Cardiovascular Diseases and Conditions Experimental Lung Transplants Health and Medicine Inflammation Primary Graft Dysfunction Reperfusion Injury Risk and Prevention Surgery Transplant Medicine Vascular Diseases and Conditions 318 318 1 06/19/23 20230619 NES 230619 2023 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Researchers detail new data in Cardiovascular Diseases and Conditions - Primary Graft Dysfunction. [Extracted from the article]

Keywords: St. Louis; State:Missouri; United States; North and Central America; Biomedicine; Cardiovascular Diseases and Conditions; Experimental Lung Transplants; Health and Medicine; Lung Transplantation; Lung Transplants; Organ Transplants; Physical Therapy and Rehabilitation Medicine; Primary Graft Dysfunction; Pulmonary Surgical Procedures; Reperfusion Injury; Respiratory Therapy; Risk and Prevention; Surgery; Transplant Medicine; Vascular Diseases and Conditions EN St. Louis State:Missouri United States North and Central America Biomedicine Cardiovascular Diseases and Conditions Experimental Lung Transplants Health and Medicine Lung Transplantation Lung Transplants Organ Transplants Physical Therapy and Rehabilitation Medicine Primary Graft Dysfunction Pulmonary Surgical Procedures Reperfusion Injury Respiratory Therapy Risk and Prevention Surgery Transplant Medicine Vascular Diseases and Conditions 103 103 1 06/05/23 20230605 NES 230605 2023 JUN 8 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators discuss new findings in Cardiovascular Diseases and Conditions - Primary Graft Dysfunction. Of 773 lung transplant recipients, PGD grade 3 developed in 204 (26%) at any time in the first 72 hours after lung transplantation. [Extracted from the article]

Keywords: San Francisco; State:California; United States; North and Central America; Biomedicine; Cardiovascular Diseases and Conditions; Experimental Lung Transplants; Health and Medicine; Primary Graft Dysfunction; Reperfusion Injury; Surgery; Transplant Medicine; Vascular Diseases and Conditions EN San Francisco State:California United States North and Central America Biomedicine Cardiovascular Diseases and Conditions Experimental Lung Transplants Health and Medicine Primary Graft Dysfunction Reperfusion Injury Surgery Transplant Medicine Vascular Diseases and Conditions 324 324 1 05/02/23 20230504 NES 230504 2023 MAY 4 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Current study results on Cardiovascular Diseases and Conditions - Primary Graft Dysfunction have been published. Keywords for this news article include: San Francisco, California, United States, North and Central America, Biomedicine, Cardiovascular Diseases and Conditions, Experimental Lung Transplants, Health and Medicine, Primary Graft Dysfunction, Reperfusion Injury, Surgery, Transplant Medicine, Vascular Diseases and Conditions, University of California San Francisco (UCSF). [Extracted from the article]

Keywords: Cardiovascular Diseases and Conditions; Central Nervous System Agents; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; FDA Actions; Fatty Acid Derivative Anticonvulsants; Headache and Migraine; Health and Medicine; Information Technology; Information and Data Security; Michigan Medicine - University of Michigan; Nervous System Diseases and Conditions; Neurology; Pharmaceuticals; Primary Graft Dysfunction; Primary Headache Diseases and Conditions; Reperfusion Injury; Risk and Prevention; Surgery; Valproic Acid; Valproic Acid Therapy; Vascular Diseases and Conditions EN Cardiovascular Diseases and Conditions Central Nervous System Agents Clinical Research Clinical Trials and Studies Drugs and Therapies FDA Actions Fatty Acid Derivative Anticonvulsants Headache and Migraine Health and Medicine Information Technology Information and Data Security Michigan Medicine - University of Michigan Nervous System Diseases and Conditions Neurology Pharmaceuticals Primary Graft Dysfunction Primary Headache Diseases and Conditions Reperfusion Injury Risk and Prevention Surgery Valproic Acid Valproic Acid Therapy Vascular Diseases and Conditions 2023 FEB 23 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Hundreds of thousands of Americans with heart failure are sick enough to benefit from a transplant, yet only around 4,000 heart transplants are performed annually. The condition, known as primary graft dysfunction, is responsible for nearly 40% of early deaths after heart transplant and can still predictably occur despite newer machine heart perfusion technology. [Extracted from the article]